We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Citations Search

Sort By:

MAbs 10(3), 370-379. Development and characterization of an anti-rituximab monoclonal antibody panel.

  2018

Tada, M., Suzuki, T., and Ishii-Watabe, A.

 

Notes: These authors used the CytoTox®-Glo Assay as the readout for a CDC assay, and the ADCC reporter bioassay, to evaluate the potency of anti-rituximab antibodies. 

  (5007)

Expand Full Notes »

Mol. Ther. Oncolytics 6, 57–68. Efficacy and safety of doubly-regulated vaccinia virus in a mouse xenograft model of multiple myeloma. 2017

Futami, M., Sato, K., Miyazaki, K., Suzuki, K., Nakamura, T. and Tojo, A.

Notes: Multiple myeloma cells show strong susceptibility to vaccinia virus. Here, a modified vaccinia virus with the essential viral gene B5R regulated by let-7 microRNA is used to specifically target cancer cells. Wild-type virus lead to mouse death via viral toxicity. Regulated vaccinia virus led to tumor regression and remained localized to the myeloma site in mice. Viral and tumor localization was imaged in live mice using the ONE-Glo™ Luciferase Assay System and ViviRen™ In Vivo Renilla Luciferase Substrate, respectively. (5141)

Expand Full Notes »

Biochem. Pharmacol. 136, 62–75. Real-time analysis of the binding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes. 2017

Kilpatrick, L. E., Friedman-Ohana, R., Alcobia, D. C., Riching, K., Peach, C. J., Wheal, A. J., Briddon, S. J., Robers, M. B., Zimmerman, K., Machleidt, T., Wood, K. V., Woolard, J. and Hill, S. J.

Notes: Vascular endothelial growth factor (VEGF) receptor interactions are observed using the NanoBRET™ Protein-Protein Interaction System. A novel method of labeling VEGF at a single N-terminal cysteine (TMR) to maintain full activity is presented. NanoLuc®-VEGFR2 and VEGF-TMR are used in conjunction to monitor an interaction and internalization into intracellular endosomes. The effect of receptor tyrosine kinase inhibitors such as Cediranib and vandetanib on internalization in living cells is assessed. (5060)

Expand Full Notes »

Oncogene , (Epub ahead of print). Topoisomerase IIα mediates TCF-dependent epithelial-mesenchymal transition in colon cancer. 2016

Zhou, Q., Abraham, A.D., Li, L., Babalmorad, A., Bagby, S., Arcaroli, J.J., Hansen, R.J., Valeriote, F.A., Gustafson, D.L., Schaack, J., Messersmith, W.A. and LaBarbera, D.V.

Notes: Topoisomerase IIα was identified as an important factor for metastasis of colorectal cancer involving the wnt signaling pathway. Microspheroids of SW620 cells, generated through ultra-low attachment plates, were used in the study. Activation of the wnt pathway was monitored with a reporter assay measured with the ONE-Glo™ Luciferase Assay System. Duplicate cells were monitored for viability with the CellTiter-Glo® 3D Cell Viability Assay. An ATP-competitive, N-terminal inhibitor of topoisomerase IIα was examined for cytotoxicity to the microspheroids. Cytotoxicity was monitored from 6–72 hours of exposure to the inhibitor using the CellTox™ Green Cytotoxicity Assay. Cytotoxicity increased over time with the inhibitor, and controls were essentially unaffected. (4708)

Expand Full Notes »

Nucl. Acids Res. 42, e28. DNA transposition by protein transduction of the piggyBac transposase from lentiviral Gag precursors. 2014

Cai, Y., Bak, R.O., Krogh. L.B., Staunstrup, N.H., Moldt, B., Corydon, T.J., Schrøder, L.D. and Mikkelsen, J.G.

Notes: Researchers were looking for alternative methods to using transposase vectors carried by lentiviruses to insert genes into cellular DNA without the cytotoxicity that may occur if the transposase gene integrated into the genome. In this paper, the authors worked out a method to generate lentiviral particles that carried the transposase protein for delivery of genes at an equal efficiency as the conventional plasmid-based method. The reporter gene NanoLuc® luciferase was amplified from the pNL1.1[Nluc] Vector and cloned into a gag-pol-integrase-defective packaging construct. Firefly luciferase was cloned into the PB transposon lentiviral vector. Gag-pol constructs expressing the hyperactive piggyback (PB) transposase were also created. Lentiviral particles (LPs) were generated by cotransfection of several plasmids into 293T cells. One day prior to transduction, HeLa cells were seeded at a density of 104 cells/well in a 96-well plate, then NanoLuc® LPs with or without pseudotyping by Vesicular Stomatitis Virus envelope glycoprotein were added. After 48 hours, luminescence was measured using the Nano-Glo® Luciferase Assay System. To analyze how well the firefly luciferase gene was transferred, HaCaT and ARPE-19 cells were seeded at 1,000 cells/well in a 96-well plate one day before transduction with increasing amounts of either wildtype or mutated PBase/firefly luciferase transposon LPs. After ten days, the transduced cells were assessed for luminescence using the ONE-Glo™ Luciferase Assay System. HEK293 cells, primary keratinocytes and normal human dermal fibroblasts were seeded at 5,000 cells/well in 24-well plates the day before transduction and then incubated with either wildtype or mutated PBase/firefly luciferase transposon LPs. After eight days, firefly luminescence was measured. (4448)

Expand Full Notes »

Proc. Natl. Acad. Sci. USA 106, 3473–3478. Generation of recombinant lymphocytic choriomeningitis virus with trisegmented genomes stably expressing two additional genes of interest. 2009

Emonet, S.F., Garidou, L., McGavern, D.B. and de la Torre, J.C.

Notes: The lymphocytic choriomeningitis virus (LCMV) was used as a model to create a trisegmented recombinant arenavirus in which viral genes were replaced by a gene of interest. One such engineered virus, r3LCMV CAT/FLuc, was used in a pilot screen to identify anti-arenaviral compounds. Firefly luciferase (FLuc) activity was measured using the ONE-Glo™ Luciferase Assay System. (3957)

Expand Full Notes »